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ORIGINAL ARTICLE
Effects of Dapagliflozin on 24-Hour Glycemic
Control in Patients with Type 2 Diabetes:
A Randomized Controlled Trial
Robert R. Henry, MD,1,2 Poul Strange, MD, PhD,3 Rong Zhou, PhD,4 Jeremy Pettus, MD,1,2
Leon Shi, PhD,3 Sergey B. Zhuplatov, MD, PhD,5,* Traci Mansfield, PhD,5,*
David Klein, MD, PhD,4 and Arie Katz, MD5,*
Abstract
Background: Glycated hemoglobin (HbA1c) and measures of short-term glycemia do not fully capture daily
patterns in plasma glucose dynamics. This study evaluated 24-h glycemic profiles in patients with type 2
diabetes (T2D) initiated on dapagliflozin treatment using continuous glucose monitoring (CGM).
Methods: This randomized double-blind placebo-controlled multicenter parallel-design 4-week study compared
dapagliflozin (10mg/d; n= 50) with placebo (n= 50) in adult patients with T2D uncontrolled (HbA1c 7.5%–
10.5%) on either stable doses of metformin monotherapy (‡1500mg/d) or insulin (‡30U/d with or without up to
two oral antidiabetes drugs). CGM was used to measure 24-h glycemic profiles for 7 days pretreatment and during
week 4 of treatment. The primary outcome was change from baseline in 24-h mean glucose (MG) at week 4.
Results: The 24-h MG decreased 18.2mg/dL with dapagliflozin and increased 5.8mg/dL with placebo
(P< 0.001). The proportion of time spent in the target glucose range (70–180mg/dL) increased significantly
with dapagliflozin versus placebo (69.6% vs. 52.9%; P< 0.001), with a small (0.3%) increase in time spent in
the hypoglycemic range (<70mg/dL), driven by those on background insulin therapy. Dapagliflozin reduced
postprandial glucose and significantly decreased overall glucose variability. Few events of symptomatic hy-
poglycemia occurred. The most common adverse event was urinary tract infection (6% in each treatment arm).
Conclusions: Compared with placebo, dapagliflozin improved measures of glycemic control and variability as
assessed by CGM. Glycemic improvements were more pronounced in the group on background metformin than
those receiving basal insulin.
Keywords: Continuous glucose monitoring, Daily glycemic variability, Dapagliflozin, SGLT2 inhibitor.
Introduction
Glycated hemoglobin (HbA1c), which reflects aver-age overall glycemia for a period of *3 months, is a
well-validated surrogate for the microvascular complications
of diabetes mellitus.1 Although HbA1c and other measures of
more short-term glycemia are useful for monitoring patients’
responses to treatment over time, they do not capture daily
patterns in plasma glucose dynamics and are poor predictors
of hypoglycemia.2,3 Other glycemia measures, such as fast-
ing plasma glucose (FPG), may also fall short of assessing
glycemic control.4
Continuous glucose monitoring (CGM) can provide in-
formation about glucose dynamics not gleaned from static
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glucose measurements. The use of CGM among patients has
been shown to reduce time spent outside of glucose targets
for a 24-h period, lower HbA1c, and more accurately identify
hypoglycemic episodes,5–7 thereby helping to characterize
hypoglycemia risk.7,8
Dapagliflozin is a highly selective reversible inhibitor of
sodium–glucose cotransporter 2 (SGLT2) approved for the
treatment of type 2 diabetes (T2D). By inhibiting SGLT2,
dapagliflozin increases urinary glucose excretion, thereby low-
ering blood glucose concentrations. Once-daily oral adminis-
tration of dapagliflozin results in rapid and sustained glucosuria
for 24 h in patients with T2D, inhibiting up to 40% of filtered
glucose from reabsorption by the kidneys, for a glucose excre-
tion rate of up to 3g/h (&70g/d).9 The pharmacodynamic
properties of dapagliflozin have translated into consistent im-
provements in glycemic control in a wide spectrum of patients
with T2D, both as monotherapy and in combination with other
oral antidiabetes drugs (OADs) and/or insulin.10
The objective of this study was to compare the effects of
dapagliflozin versus placebo on the 24-h glycemic profile
assessed by CGM in adult patients with T2D uncontrolled on
stable doses of either metformin alone or insulin (with or
without up to two OADs).
Materials and Methods
Study design
This was a randomized double-blind placebo-controlled
multicenter parallel-design study (ClinicalTrials.gov identi-
fier: NCT02429258) conducted at 34 centers in the United
States between May and October 2015. Supplementary
Figure S1 (Supplementary Data are available online at http://
online.liebertpub.com/suppl/doi/10.1089/dia.2018.0052) depicts
the study design. An equal number of patientswere recruited to
each stratum (insulin or metformin) before randomization.
Randomization to dapagliflozin or placebo was performed
using an Interactive Voice Response System/Interactive Web
Response System in a 1:1 ratio; metformin or insulin back-
ground therapy was used as stratum in the randomization.
The Dexcom G4 PLATINUM CGM system (Dexcom,
Inc., San Diego, CA) was used to measure patients’ interstitial
glucose concentrations. A 7-day assessment using the CGM
system was performed during the lead-in period (days -14 to
-7) and during week 4 of treatment (days 21 to 28). The CGM
system recorded data every 5min (288 times per day). Both
patients and investigators were blinded to CGM readings.
Patients were instructed to calibrate the CGM device by re-
cording a self-monitored blood glucose value minimally every
12h according to the manufacturer’s instructions.
Participants
Adult patients (aged ‡18 to £75 years) with T2D were
eligible if they had been treated with either a stable dose of
metformin alone (‡1500mg/d) or a stable dose of insulin
(‡30U/d with or without up to twoOADs) for at least 8 weeks
before screening.
At screening, patientswere required to have aHbA1c ‡7.5%
and £10.5%, body mass index (BMI) £45kg/m2, and fasting
C-peptide concentration ‡1.5 ng/mL. Patients also had to
demonstrate ‡70% compliance with the CGM device during
the lead-in period, including periodic device calibrations and
glucose reading verification per themanufacturer’s specification.
Patients were excluded if they had a significant cardio-
vascular history (per investigator’s discretion), history of
type 1 diabetes or diabetic ketoacidosis within the past 12
months, bariatric surgery or lap-band procedure, bladder
cancer, orthostatic hypotension within the past 6 months,
uncontrolled hypertension, or ‡2 episodes of severe hypo-
glycemia during the previous 12 months. Patients were also
excluded if they had received any medication known to affect
glucose metabolism (e.g., glucocorticoids) or any prescrip-
tion or over-the-counter weight-loss medications during the
previous 3 months.
The institutional review board for each site approved the
study design and methods in accordance with the principles
defined by the Declaration of Helsinki. All participants pro-
vided written informed consent before entering the study.
Treatment
The study consisted of a 1-week screening period, a 2-
week lead-in period, a 4-week treatment period, and a 1-week
follow-up period. During the treatment period, patients re-
ceived oral dapagliflozin once daily (10mg/d) or placebo for
4 weeks in combination with either open-label metformin
extended-release (‡1500mg/d) or open-label insulin (‡30U/d
with or without up to two open-label OADs).
Patients were instructed to continue their background dia-
betesmedication(s) as previously prescribed for the duration of
the study. Any changes in baseline medication doses were at
the discretion of the investigator. No insulin diaries or detailed
dosing information was collected. Patients in the insulin stra-
tum were allowed to take more than one type of insulin.
Beginning in the lead-in period and continuing throughout
the study, patients were asked to follow a standard diabetes
weight maintenance diet. Patients were instructed to avoid
significant changes to the timing and content of meals during
the 7-day CGM assessment period and to refrain from acet-
aminophen use. On days -13 and 22, patients were provided a
standardized breakfast (660 kilocalories, 60% carbohydrate,
15% protein, and 25% fat) and then only water through the
completion of the meal test. Postprandial glucose (PPG) was
obtained during blood draws for glucose measurements after
breakfast (0, 30, 60, 120, 180, and 240min) during the onsite
monitoring visits on these days.
Outcomes
The primary assessment was change in the 24-h mean
glucose (MG) derived from the 7-day CGM data in the sec-
ond week of the lead-in period to week 4, which was esti-
mated by dividing the area under the 24-h glucose curve
(AUC0–24) by 24 h and expressed in mg/dL. Average 24-h
glucose profiles and percentages of time in low (<70mg/dL),
normal (‡70 to £180mg/dL), and high (>180mg/dL) gly-
cemic ranges were secondary end points assessing glucose
parameters from CGM data. Other secondary end points were
2-h PPG (estimated by dividing the area under the 2-h glu-
cose curve by 2 h from the standardized meal test), HbA1c,
FPG, and fructosamine.
Glucose variability end points included mean amplitude of
glucose excursion (MAGE), ‘‘distance traveled,’’ and standard
deviation (SD) of 24-h glucose. Patients’ change in 24-h
MAGE was defined as the mean of the absolute difference
from nadir to peak for those differences that exceeded the SD
716 HENRY ET AL.
of the CGM assessments for 24 h.11 The ‘‘distance traveled’’
arc length of the curve for 24 h was approximated using the
trapezoid rule from the finite Fourier approximation of glucose
concentrations for 24 h of consecutive glucosemeasurement.12
Safety
The safety population included all patients who received at
least one dose of investigational product, analyzed according
to the type of agent received. Safety evaluations included the
frequency and severity of adverse events (AEs), reported events
of hypoglycemia, serum (hematology and clinical chemistry)
and urine laboratory tests, electrocardiograms, physical exam-
inations, and vital signs. AEs were classified using theMedical
Dictionary for Regulatory Activities (version 17.1) system of
nomenclature. A treatment-emergent AE (TEAE) was defined
as any AE that started on or after the first dose of randomized
investigational product or occurred before the first dose and
worsened in severity.
Statistics
The intention-to-treat (ITT) population included all ran-
domized patients who received at least one dose of randomized
treatment, and this was used for all efficacy analyses. For the
primary end point of 24-h MG, the least-squares mean (LSM),
standard errors of LSM, two-sided 95% confidence intervals
(CIs) for themean changewithin each treatment group, and the
LSM difference between treatment groups were calculated.
The changes in 24-h MG from baseline to week 4 were ana-
lyzed using an analysis of covariance (ANCOVA)model, with
change in 24-h MG as the dependent variable, dapagliflozin
treatment and metformin/insulin stratum as factors, and
baseline 24-h MG as a covariate.
Secondary end points were analyzed using an ANCOVA
model similar to the one described for the primary end point.
To account for missing data in the analyses of the primary and
secondary outcome variables, linear mixed-effects models
were used.
The primary end point was tested using a= 0.05. The study
had 80% power to detect a 14.5-mg/dL difference in the
primary outcome measure for the overall population. Nom-
inal P values and/or 95%CIs are presented, where applicable,
for the secondary and exploratory end points; however, in-
ferences for treatment differences with respect to these end
points should not be made.
Any 24-h CGM profiles with <260 (non-inclusive) data
points were censored out, including the half-day profiles on
the days when the CGM device was inserted or terminated.
CGM profiles with >260 and <288 data points were consid-
ered valid, and any missing data points were imputed by
linear or cubic spline interpolation.
Results
Study disposition
A total of 100 patients were randomized (dapagliflozin,
n= 50; placebo, n= 50) and are included in both the safety and
ITT populations (Supplementary Fig. S2). The dapagliflozin
group included 23 patients in the metformin stratum and 27
patients in the insulin stratum, and the placebo group included
25 patients each in the metformin and insulin strata. The mean
Table 1. Demographics and Baseline Characteristics of the Study Population
Characteristics
Overall (N= 100) Metformin stratum (n = 48) Insulin stratum (n = 52)
Dapagliflozin
(n= 50)
Placebo
(n = 50)
Dapagliflozin
(n = 23)
Placebo
(n= 25)
Dapagliflozin
(n = 27)
Placebo
(n = 25)
Age at randomization, years,
mean (SD)
56.9 (7.1) 56.8 (9.7) 56.0 (6.9) 53.2 (10.7) 57.7 (7.3) 60.4 (7.1)
Gender, n (%)
Male 26 (52.0) 25 (50.0) 13 (56.5) 12 (48.0) 13 (48.1) 13 (52.0)
Female 24 (48.0) 25 (50.0) 10 (43.5) 13 (52.0) 14 (51.9) 12 (48.0)
Race, n (%)
White 39 (78.0) 36 (72.0) 18 (78.3) 18 (72.0) 21 (77.8) 18 (72.0)
Black or African American 11 (22.0) 14 (28.0) 5 (21.7) 7 (28.0) 6 (22.2) 7 (28.0)
Ethnicity, n (%)
Hispanic or Latino 14 (28.0) 16 (32.0) 8 (34.8) 7 (28.0) 6 (22.2) 9 (36.0)
Not Hispanic or Latino 36 (72.0) 34 (68.0) 15 (65.2) 18 (72.0) 21 (77.8) 16 (64.0)
Duration of diabetes, years,
mean (SD)
10.5 (6.0) 12.3 (7.4) 6.7 (4.0) 9.5 (6.4) 13.9 (5.6) 15.6 (7.3)
Weight, kg, mean (SD) 96.5 (23.5) 96.0 (20.0) 90.6 (21.2) 93.8 (23.5) 101.6 (24.6) 98.1 (15.9)
BMI, kg/m2, mean (SD) 34.3 (5.9) 33.2 (5.6) 32.9 (6.2) 32.0 (5.6) 35.5 (5.5) 34.5 (5.4)
SBP, mmHg, mean (SD) 128.9 (13.5) 127.0 (13.7) 125.7 (11.1) 124.9 (13.6) 131.7 (14.9) 129.1 (13.7)
DBP, mmHg, mean (SD) 77.3 (8.2) 77.3 (9.4) 76.8 (8.5) 76.8 (9.6) 77.8 (9.5) 77.3 (8.2)
Heart rate, beats/min, mean (SD) 71.5 (10.4) 75.2 (10.4) 71.0 (11.1) 73.6 (7.8) 71.9 (9.9) 76.9 (12.5)
eGFR, mL/min/1.73m2,
mean (SD)
91.4 (22.0) 89.7 (23.6) 93.6 (17.3) 94.5 (26.2) 89.4 (25.5) 84.8 (20.0)
HbA1c, %, mean (SD) 8.31 (0.79) 8.37 (0.81) 8.02 (0.78) 8.23 (0.86) 8.56 (0.71) 8.51 (0.75)
FPG, mg/dL, mean (SD) 163.6 (69.4) 170.3 (57.0) 155.7 (35.3) 169.4 (51.3) 170.3 (89.0) 171.3 (63.3)
2-h PPG, mg/dL, mean (SD) 223.3 (58.4) 231.5 (46.4) 224.1 (63.7) 231.9 (47.2) 222.6 (54.7) 231.2 (46.6)
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c,
glycated hemoglobin; PPG, postprandial glucose; SBP, systolic blood pressure; SD, standard deviation.
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FIG. 1. Changes from baseline. (A) 24-h mean (SE) glucose, with treatment difference for LSM change from baseline
(mg/dL) in the ITT population. (B) Comparison of change from baseline in mean 24-h glucose profile at week 4 as shown by
MADz in the overall population (time 0 to 24 h means midnight to midnight; the black line represents the treatment DAPA–
PBO difference; when the difference between the two groups’ change from baseline [blue and green lines for DAPA and
PBO, respectively] is outside the MADz red lines [95th percentiles], the two treatments are statistically different at that time
of day). (C) Change from baseline in time spent (%) in plasma glucose ranges from baseline to week 4 in the ITT
population. The arrows denote the percentages of time with glucose <70mg/dL. CI, confidence interval; DAPA, dapagli-
flozin; ITT, intention-to-treat; LSM, least-squares mean; MADz, maximum absolute deviation from zero; PBO, placebo;
SE, standard error.
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dailymetformin dose in themetformin stratumwas 1977.1mg,
and the mean daily insulin dose in the insulin stratum was 52.9
units. In the insulin stratum, 28.8%of patients used long-acting
insulin alone or with OAD(s). The remaining patients in the
insulin stratum used short- or intermediate-acting insulin alone
or in combination with long-acting insulin and/or OAD(s)
(Supplementary Table S1).
A total of 97 patients with adequate data for both lead-in and
week-4 CGM measures completed the study: two patients in
the dapagliflozin groupwithdrew consent and did not complete
the study and one patient in the placebo group was withdrawn
because of a protocol violation (Supplementary Fig. S2).
Patient demographics and baseline characteristics
Patient demographics and baseline clinical characteristics
were generally similar across treatment groups (Table 1). Pa-
tients in the insulin stratum tended to be older, with higher BMI,
higher HbA1c, higher systolic blood pressure, and a longer
duration of diabetes than patients in the metformin stratum.
Comparison of the effects of dapagliflozin on MG
within the overall study population
In the overall population, 24-h MG decreased in the da-
pagliflozin group from a baseline of 177.9 to 160.7mg/dL at
A
B
FIG. 2. ITT population changes from baseline for the metformin and insulin strata. (A) 24-h mean (SE) glucose for the
strata, with treatment difference for LSM change from baseline (mg/dL). (B) Comparison of change from baseline in mean
24-h glucose profile at week 4 as shown by MADz. CI, confidence interval; DAPA, dapagliflozin; ITT, intention-to-treat;
LSM, least-squares mean; MADz, maximum absolute deviation from zero; PBO, placebo; SE, standard error.
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week 4 and increased from 182.6 to 187.5mg/dL in the
placebo group (Fig. 1A). The treatment difference for change
from baseline between dapagliflozin and placebo in 24-h MG
was -24.0mg/dL (P < 0.001). The mean 24-h CGM glucose
profile showed a notable downward shift across the overall
24-h profile from baseline to week 4 in the dapagliflozin
group, whereas glucose concentrations remained the same or
slightly increased across the 24-h profile for patients in the
placebo group (Fig. 1B; Supplementary Fig. S3).
Compared with baseline, the mean percentage of time with
CGM glucose values within the target range (‡70 and £180
mg/dL) increased with dapagliflozin treatment (+12.2%; 95%
CI: 7.0 to 17.3), whereas it decreased with placebo (-2.8%;
95% CI: -7.9 to 2.2; Fig. 1C; Supplementary Table S2). The
mean percentage of time spent in a hyperglycemic range (glu-
cose >180mg/dL) at week 4 decreased in the dapagliflozin
group (-12.6%; 95% CI: -17.8 to -7.3) and increased in the
placebo group (+3.5%; 95% CI: -1.7 to 8.7). The mean per-
centage of time spent in the hypoglycemic range (<70mg/dL) at
week 4 increased slightly with dapagliflozin (+0.3%; 95% CI:
-0.3 to 0.9) and decreased slightly with placebo (-0.6%; 95%
CI: -1.2 to -0.1). The mean percentage of time spent with
glucose <54mg/dL was 0.0% at baseline and remained 0.0% at
week 4 in both treatment groups.
Comparison of the effects of dapagliflozin on MG
within the individual strata
The addition of dapagliflozin to metformin reduced 24-h
MG from a baseline of 177.0 to 155.5mg/dL for 4 weeks
compared with an increase from 185.6 to 198.0mg/dL in
the placebo group, for an LSM difference of -36.2mg/dL at
week 4 (nominal P< 0.001; Fig. 2A). For patients in the in-
sulin stratum, 24-h MG decreased from a baseline of 178.6
to 164.8mg/dL in the dapagliflozin group and from 179.7
to 177.4mg/dL in the placebo group; the LSM difference
between dapagliflozin and placebo was -11.9mg/dL at week
4 (nominal P= 0.153; Fig. 2A).
Similar to the change in the glucose profile for the overall
population, CGM-derived glucose concentrations in the
metformin stratum decreased by*20mg/dL across the 24-h
profile with dapagliflozin treatment, and slightly increased
with placebo (Fig. 2B; Supplementary Fig. S4). In the insulin
stratum, glucose concentrations decreased by *15mg/dL
with dapagliflozin and decreased slightly with placebo
(Fig. 2B; Supplementary Fig. S5).
The increased proportion of time spent in the target range
was more pronounced for patients in the metformin stratum
(+23.8% vs placebo; nominal P < 0.001) than for patients
in the insulin stratum (+6.1% vs placebo; nominal P= 0.218;
Fig. 3; Supplementary Table S2). The mean percentage of
time spent in the hypoglycemic range was small in both the
dapagliflozin and placebo groups at baseline and week 4 in
the metformin and insulin strata. The mean percentage of
time spent in the hyperglycemic range from baseline to week
4 decreased with dapagliflozin and increased with placebo in
the metformin stratum (Fig. 3A). In the insulin stratum, a
decrease was observed in both groups (Fig. 3B).
Measures of glucose variability
Measures of glucose variability included MAGE, ‘‘dis-
tance traveled,’’ and SD of 24-h glucose. For change in
MAGE in the overall population, the difference from baseline
to week 4 between the dapagliflozin and placebo groups was
-15.3mg/dL (P = 0.010; Supplementary Table S3). The dif-
ference from baseline to week 4 between dapagliflozin and
placebo was -17.7mg/dL (nominal P= 0.040) in the met-
formin stratum and -12.9mg/dL (nominal P = 0.105) in the
insulin stratum.
The mean change in ‘‘distance traveled’’ from baseline to
week 4 in the overall population was -28.0mg/dL in the
dapagliflozin group and +9.5mg/dL in the placebo group, for
a difference between groups of -37.5mg/dL (P = 0.312;
Supplementary Table S3). The difference between the da-
pagliflozin and placebo groups at week 4 was -104.1mg/dL
(nominal P = 0.057) for the metformin stratum and +29.1
mg/dL (nominal P = 0.564) for the insulin stratum.
The mean change in SD of 24-h glucose from baseline to
week 4 in the overall population was -3.4mg/dL in the da-
pagliflozin group and +1.3mg/dL in the placebo group, for a
A
B
FIG. 3. Change from baseline in time spent (%) in plasma
glucose ranges from baseline to week 4 in the ITT population.
(A) Metformin stratum. (B) Insulin stratum. The arrows de-
note the percentages of time with glucose <70mg/dL. DAPA,
dapagliflozin; ITT, intention-to-treat; PBO, placebo.
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difference between groups of–4.7mg/dL (P= 0.037; Supple-
mentary Table S3). The difference between the dapagliflozin
and placebo groups at week 4 was -6.8mg/dL (nominal
P= 0.041) for the metformin stratum and -2.7mg/dL (nominal
P= 0.382) for the insulin stratum.
Additional glycemic end points
Changes from baseline to week 4 in FPG, HbA1c, and 2-h
PPG as measured with blood sampling in the overall popu-
lation, the metformin stratum, and the insulin stratum are
shown in Table 2. A statistically significant decrease from
baseline at week 4 with dapagliflozin compared with that of
placebo was observed for all three parameters in the overall
population and for some parameters in the individual strata.
The results in the overall population for 2-h PPG are more
similar to those observed in the insulin stratum, whereas
those for FPG are more similar to what was observed in the
metformin stratum.
Safety evaluation
Overall, 28 patients (28.0%) had a TEAE during the study
(dapagliflozin, n = 18 [36.0%]; placebo, n = 10 [20.0%];
Table 3). Most TEAEs occurred in one patient per treatment
group (Supplementary Table S4). The most common AE was
urinary tract infection, reported in three patients (6%) in each
of the dapagliflozin and placebo groups (Table 3). AEs were
generally evenly distributed between the metformin and in-
sulin strata. The majority of TEAEs were considered mild
(71.4%) or moderate (25.0%). One patient in the dapagli-
flozin group had a severe TEAE of elevated blood creatinine
and decreased glomerular filtration rate, which did not result
in discontinuation.
One patient in the dapagliflozin group experienced a serious
AE of worsening urinary tract infection before initiating study
treatment with dapagliflozin; the serious AE resolved, and the
patient continued into the study. Overall, two patients had an
AE leading to discontinuation of study drug (both in the da-
pagliflozin group): one patient experienced abdominal dis-
comfort, flatulence, and headache starting on study day 1, and
the other patient had fungal genital infection starting on day 27.
Six patients (three in each of the dapagliflozin and placebo
groups) in the insulin stratum had documented symptomatic
or probable symptomatic hypoglycemic events, all of which
were considered nonsevere. Two patients (both in the da-
pagliflozin group: one patient in the insulin stratum and the
other patient in the metformin stratum) had nonsevere
asymptomatic hypoglycemic events.
Overall, no clinically meaningful changes from baseline
were observed in clinical laboratory tests, vital signs, or
physical examination; however, decreases in weight and
blood pressure were observed for patients treated with da-
pagliflozin. From baseline to week 4, mean weight decreased
from 96.5 to 94.9 kg, respectively, mean systolic blood
pressure decreased from 128.9 to 126.4mmHg, and mean
diastolic blood pressure decreased from 77.3 to 76.2mmHg.
Discussion
This is one of the first studies, and the largest, to use CGM
to assess the effects of the SGLT2 inhibitor dapagliflozin on
the 24-h glucose profile and daily glucose variability among
patients with T2D. Guidelines recommend metformin
monotherapy as first-line treatment, with the rapid (after 3
months) addition of a second or third antidiabetes agent
and/or insulin if glycemic goals are not met.13 A large ret-
rospective study showed that*85% of patients with T2D in
primary care are prescribed metformin and almost 25% re-
ceive insulin.14 Thus, the patients included in this study, on
background metformin or insulin (plus up to two OADs),
represent the diverse population of patients with T2D com-
monly encountered in clinical practice.
The results of this study showed significant improvements
in 24-h glycemic control among patients on stable doses of
metformin alone or insulin (with or without up to two OADs)
treated with dapagliflozin. In the overall population, treat-
ment with dapagliflozin resulted in significant reductions in
the primary end point of 24-h MG relative to placebo after 4
weeks of treatment, as well as significant increases in time
spent in the target range (‡70 and £180mg/dL), improve-
ments in glycemic parameters (FPG, 2-h PPG, HbA1c, and
fructosamine), and glucose variability as assessed byMAGE.
When the results were examined by background medica-
tion stratum (metformin vs. insulin), statistically significant
improvements in glucose parameters relative to placebo were
observed in the metformin stratum but not in the insulin
stratum. Of note, the study was powered to detect differences
between dapagliflozin and placebo for the overall population,
not for individual strata. Patients in the insulin stratum tended
to be older and have higher BMI, FPG, and HbA1c at baseline
than patients in the metformin stratum. In addition, patients in
the insulin stratum had longer disease duration. This, along
with the fact that they were also treated with up to two OADs,
suggests that they had more advanced disease and less residual
islet function than those in the metformin group.
Table 3. Overview of Adverse Events,
Including Treatment-Emergent Adverse Events
in ‡2 Patients: Safety Population
Category, n (%)
Dapagliflozin
(n = 50)
Placebo
(n = 50)
Overall
(N= 100)
Patients with any AE 21 (42) 14 (28) 35 (35)
Patients with any TEAE 18 (36) 10 (20) 28 (28)
Urinary tract infection 3 (6) 3 (6) 6 (6)
Upper respiratory
tract infection
1 (2) 2 (4) 3 (3)
Anemia 1 (2) 1 (2) 2 (2)
Oropharyngeal pain 2 (4) 0 2 (2)
Patients with any SAE 1 (2) 0 1 (1)
Patients with any
AE leading to
discontinuation
of drug
2 (4) 0 2 (2)
Deaths 0 0 0
Patients with multiple events in the same category were counted
only once in that category. Patients with events in more than one
category were counted once in each of those categories.
Safety population consisted of all patients who received at least
one dose of treatment, analyzed according to the type of investi-
gational product received.
AE, adverse event; SAE, serious adverse event; TEAE, treatment-
emergent adverse event.
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Differences between insulin and metformin strata may also
reflect the expected greater effect of SGLT2 inhibitors on
mealtime glucose excursions, most prominent in early diabetes.
Patients in the metformin and insulin strata had similar esti-
mated glomerular filtration rate values at baseline; thus, dif-
ferential effects could not be attributed to a diminished effect of
SGLT2 inhibitors because of worse kidney function in the in-
sulin group. Although it is not known, patients in the metformin
stratum may have additionally received a sulfonylurea that was
discontinued before the lead-in period. A drift upward in fasting
24-h glucose is common when sulfonylureas are discontinued,
and the lack of difference from baseline with dapagliflozin may
be a reflection of this phenomenon, as evidenced by the dete-
rioration seen among the placebo-treated patients.
The differences in outcomes between the metformin and
insulin strata may also be a result of the study methodology.
Patients in the insulin stratum were allowed to use rapid-acting
mealtime insulin as part of the stable insulin dose regimen, and
there was no run-in period to allow for restabilization of the
daily insulin dose after initiating dapagliflozin. Any decrease in
insulin dose, due to reductions in FPG upon adding dapagli-
flozin, may have affected efficacy measurements. Although no
detailed insulin dosing information was collected, patients’
adherence to the insulin regimen may have improved as part of
their participation in a clinical trial, potentially contributing to
reductions in MG.
Considered by many to be the gold standard for measuring
glucose variability, MAGE was developed as a refinement in
the characterization of glycemic instability and represents the
arithmetic mean of the difference between consecutive peaks
and nadirs exceeding 1 SD around the mean 24-h glucose
value.11,15,16 The usefulness of MAGE is in quantifying major
swings in glycemia while excludingminor swings. Thesemajor
swings are thought to contribute to oxidative stress, which may
play a key role in the pathogenesis of diabetic complications.17
The 24-hMG andMAGE results in this study corresponded
with the increase in time spent in the target range, and the
associated decrease in time spent in hyperglycemia
(>180mg/dL), with dapagliflozin versus placebo after 4
weeks of treatment. In the metformin stratum, this im-
provement in the glucose profile seemed most apparent
overnight, suggestive of an increase in insulin sensitivity,
which has been shown to exhibit diurnal changes.18
Although the addition of dapagliflozin increased the per-
centage of time spent with glucose <70mg/dL relative to
placebo (+1.3% vs. +0.3%, respectively), there were no se-
vere hypoglycemic events. Few patients (dapagliflozin, n= 3;
placebo, n = 3) experienced nonsevere symptomatic hypo-
glycemia, and all of these patients were in the insulin stratum.
In clinical trials of dapagliflozin, mild hypoglycemia has
been seen in*40% of those treated with dapagliflozin as an
add-on to insulin with or without other OADs.19 The lower
rate of hypoglycemia observed in this study with dapagli-
flozin plus insulin may be the result of the short duration of
evaluation (4 weeks) versus other studies (24 weeks). The
most common TEAE was urinary tract infection, which was
balanced between the dapagliflozin and placebo groups (three
patients each), and has been observed at a similar rate (&6%)
in other studies of similar populations.19,20
The effects of dapagliflozin on reducing glycemic vari-
ability in patients with T2D are in accordance with other
CGM studies on the SGLT2 inhibitor class. In a 4-week
randomized controlled study in patients with T2D (n = 60),
empagliflozin significantly reduced 24-h MG and PPG,
compared with placebo, and increased the percentage of time
spent with glucose in the target range (‡70 to <180mg/dL).21
The patient population consisted of Japanese patients who
were drug naı¨ve or treated with one OAD, which differed
from this study in which patients were treated with either
metformin monotherapy or insulin with or without up to two
OADs, with results additionally analyzed in these strata.
Similarly, in an 8-week single-arm pilot study including
patients with type 1 diabetes (n= 40), empagliflozin lowered
glycemic variability and showed a trend toward increased
time spent with glucose in the target range (‡70 to £140
mg/dL) compared with baseline, with more prominent effects
on nighttime glycemia compared with daytime glycemia.22
Canagliflozin has also demonstrated improvements in indices
of glycemic variability. In a substudy of an 18-week ran-
domized controlled trial including patients with type 1 dia-
betes (n = 89), improvements versus placebo were observed
in MG, glucose SD, and MAGE, with increased time spent
with glucose in the target range (>70 to £180mg/dL).23
In conclusion, dapagliflozin as an add-on therapy effec-
tively reduced the glycemic measures of HbA1c, FPG, and
PPG, consistent with several other trials performed as part of
the dapagliflozin development program,20,24 and demon-
strated the added benefit of stabilizing glucose concentrations
for 24 h, regardless of meal intake or other elements of daily
living. The results appear to be more robust with dapagli-
flozin plus metformin versus plus insulin, which may be an
artifact of the study design, intrinsic to the combination
regimen, or related to the patient population, with those on
insulin having more advanced disease. Further investigations
are needed to better characterize this relationship.
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